{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:25:39Z","timestamp":1791869139360,"version":"4.3.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s11864-020-00745-9","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T05:02:36Z","timestamp":1587618156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Current Treatment Options for Older Patients with Hodgkin Lymphoma"],"prefix":"10.1007","volume":"21","author":[{"given":"Jordan","family":"Carter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A.","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena","family":"Kritharis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"745_CR1","unstructured":"Surveillance E aERSP. Fast Stats: an interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. 2019. https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html."},{"key":"745_CR2","doi-asserted-by":"publisher","unstructured":"Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. 2013;161(1):76\u201386. https:\/\/doi.org\/10.1111\/bjh.12222.","DOI":"10.1111\/bjh.12222"},{"key":"745_CR3","doi-asserted-by":"publisher","unstructured":"Weekes CD, Vose JM, Lynch JC, Weisenburger DD, Bierman PJ, Greiner T, et al. Hodgkin\u2019s disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. 2002;20(4):1087\u201393. https:\/\/doi.org\/10.1200\/jco.2002.20.4.1087.","DOI":"10.1200\/jco.2002.20.4.1087"},{"key":"745_CR4","doi-asserted-by":"publisher","unstructured":"Stark GL, Wood KM, Jack F, Angus B, Proctor SJ, Taylor PR, et al. Hodgkin\u2019s disease in the elderly: a population-based study. 2002;119(2):432\u201340. https:\/\/doi.org\/10.1046\/j.1365-2141.2002.03815.x.","DOI":"10.1046\/j.1365-2141.2002.03815.x"},{"key":"745_CR5","unstructured":"Landgren O, Algernon C, Axdorph U, Nilsson B, Wedelin C, Porwit-MacDonald A, et al. Hodgkin\u2019s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. 2003;88(4):438\u201344."},{"issue":"8","key":"745_CR6","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1080\/10428190500518602","volume":"47","author":"D Feltl","year":"2006","unstructured":"Feltl D, V\u00edtek P, Z\u00e1me\u010dn\u00edk J. Hodgkin\u2019s lymphoma in the elderly: the results of 10 years of follow-up. Leuk Lymphoma. 2006;47(8):1518\u201322. https:\/\/doi.org\/10.1080\/10428190500518602.","journal-title":"Leuk Lymphoma"},{"key":"745_CR7","doi-asserted-by":"publisher","unstructured":"Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119(3):692\u20135. https:\/\/doi.org\/10.1182\/blood-2011-09-378414.","DOI":"10.1182\/blood-2011-09-378414"},{"issue":"5","key":"745_CR8","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/10428194.2018.1522435","volume":"60","author":"A Major","year":"2019","unstructured":"Major A, Jackson MW, Smith DE, Kamdar M, Rabinovitch R. Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis. Leuk Lymphoma. 2019;60(5):1234\u201343. https:\/\/doi.org\/10.1080\/10428194.2018.1522435.","journal-title":"Leuk Lymphoma"},{"key":"745_CR9","doi-asserted-by":"publisher","unstructured":"B\u00f6ll B, G\u00f6rgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. 2013;31(12):1522\u20139. https:\/\/doi.org\/10.1200\/jco.2012.45.4181.","DOI":"10.1200\/jco.2012.45.4181"},{"key":"745_CR10","doi-asserted-by":"publisher","unstructured":"Bj\u00f6rkholm M, Weibull CE, Eloranta S, Smedby KE, Glimelius I, Dickman PW. Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma\u2014a population-based study from Sweden. 2018;101(1):106\u201314. https:\/\/doi.org\/10.1111\/ejh.13090.","DOI":"10.1111\/ejh.13090"},{"key":"745_CR11","doi-asserted-by":"publisher","unstructured":"Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. 2015;126(26):2798\u20132804. doi:https:\/\/doi.org\/10.1182\/blood-2015-06-644336\/","DOI":"10.1182\/blood-2015-06-644336\/"},{"issue":"10","key":"745_CR12","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.3109\/10428194.2013.876496","volume":"55","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, et al. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma. 2014;55(10):2328\u201334. https:\/\/doi.org\/10.3109\/10428194.2013.876496.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"745_CR13","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.clml.2017.09.009","volume":"17","author":"G Goyal","year":"2017","unstructured":"Goyal G, Maldonado EB, Fan TJ, Kanmanthareddy A, Silberstein PT, Go RS, et al. Treatment patterns and outcomes in early-stage Hodgkin lymphoma in the elderly: a National Cancer Database analysis. Clin Lymphoma Myeloma Leuk. 2017;17(12):812\u20138. https:\/\/doi.org\/10.1016\/j.clml.2017.09.009.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"745_CR14","doi-asserted-by":"publisher","unstructured":"Engert A, Ballova V, Haverkamp H, Pfistner B, Josting A, D\u00fchmke E, et al. Hodgkin\u2019s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin\u2019s Study Group. 2005;23(22):5052\u201360. https:\/\/doi.org\/10.1200\/jco.2005.11.080.","DOI":"10.1200\/jco.2005.11.080"},{"issue":"25","key":"745_CR15","doi-asserted-by":"publisher","first-page":"6005","DOI":"10.1182\/blood-2011-12-396556","volume":"119","author":"SJ Proctor","year":"2012","unstructured":"Proctor SJ, Wilkinson J, Jones G, Watson GC, Lucraft HH, Mainou-Fowler T, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood. 2012;119(25):6005\u201315. https:\/\/doi.org\/10.1182\/blood-2011-12-396556.","journal-title":"Blood"},{"issue":"Suppl 1","key":"745_CR16","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1182\/blood-2018-99-112178","volume":"132","author":"AM Evens","year":"2018","unstructured":"\u2022 Evens AM, Connors JM, Younes A, Ansell SM, Kim WS, Radford J, et al. Older patients (pts) with previously untreated classical Hodgkin lymphoma (cHL): A detailed analysis from the phase 3 ECHELON-1 study. Blood. 2018;132(Suppl 1):1618. https:\/\/doi.org\/10.1182\/blood-2018-99-112178. Modified PFS was similar between groups, at 70.3% and 71.4% in A+AVD and ABVD, respectively. Grade 3 to 4 toxicity, the majority of which was either neutropenia or peripheral neuropathy, was more prevalent with A+AVD at 88% vs 80% in ABVD, with 13% in the ABVD experiencing a pulmonary adverse event, compared with 2% of those receiving A+AVD.","journal-title":"Blood"},{"issue":"Supplement_1","key":"745_CR17","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1182\/blood-2019-124141","volume":"134","author":"AM Rodday","year":"2019","unstructured":"Rodday AM, Hahn TE, Kumar AJ, Lindenauer PK, Friedberg JW, Evens AM, et al. Treatment with full chemotherapy regimens in older adults with Hodgkin lymphoma improves 3-year overall survival, but less than half receive full regimens. Blood. 2019;134(Supplement_1):1563. https:\/\/doi.org\/10.1182\/blood-2019-124141.","journal-title":"Blood"},{"key":"745_CR18","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0541","volume-title":"Long-term survival rates of patients with stage III\u2013IV Hodgkin lymphoma according to age, sex, race, and socioeconomic status, 1984\u20132013","author":"Y Li","year":"2018","unstructured":"Li Y, Sun H, Yan Y, Sun T, Wang S, Ma H. Long-term survival rates of patients with stage III\u2013IV Hodgkin lymphoma according to age, sex, race, and socioeconomic status, 1984\u20132013; 2018. https:\/\/doi.org\/10.1634\/theoncologist.2017-0541."},{"issue":"11","key":"745_CR19","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1093\/annonc\/mdv359","volume":"26","author":"MJ Bishton","year":"2015","unstructured":"Bishton MJ, Hubbard R, Witherall R, Jones SG, Richardson F, James EJ, et al. Era-by-era improvement in survival for elderly patients with Hodgkin lymphoma; outcome data from a large population-based cohort. Ann Oncol. 2015;26(11):2356\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdv359.","journal-title":"Ann Oncol"},{"issue":"9976","key":"745_CR20","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","volume":"385","author":"K Behringer","year":"2015","unstructured":"Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2019s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015;385(9976):1418\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(14)61469-0.","journal-title":"Lancet"},{"key":"745_CR21","doi-asserted-by":"publisher","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. 2018;378(4):331\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1708984.","DOI":"10.1056\/NEJMoa1708984"},{"key":"745_CR22","doi-asserted-by":"publisher","unstructured":"van Spronsen DJ, Janssen-Heijnen MLG, Breed WPM, Coebergh JWW, van Spronsen DJJAH. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma, 1993\u20131996. 1999;78(7):315\u20139. https:\/\/doi.org\/10.1007\/s002770050521.","DOI":"10.1007\/s002770050521"},{"key":"745_CR23","doi-asserted-by":"publisher","unstructured":"Levis A, Anselmo AP, Ambrosetti A, Adamo F, Bertini M, Cavalieri E, et al. VEPEMB in elderly Hodgkin\u2019s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol. 2004;15(1):123\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdh012.","DOI":"10.1093\/annonc\/mdh012"},{"key":"745_CR24","doi-asserted-by":"publisher","unstructured":"Evens AM, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. 2018;36(30):3015\u201322. https:\/\/doi.org\/10.1200\/jco.2018.79.0139. Patients received 2 lead-in doses of single-agent BV followed by 6 cycles of AVD and then 4 more cycles of BV. The 2-year PFS and OS rates were 85% and 92%, respectively, and there appeared to be less toxicity (especically peripheral neuropathy) compared with other trials utilizing BV in the frontline setting.","DOI":"10.1200\/jco.2018.79.0139"},{"key":"745_CR25","doi-asserted-by":"publisher","unstructured":"Eich HT, Diehl V, G\u00f6rgen H, Pabst T, Markova J, Debus J, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. 2010;28(27):4199\u2013206. https:\/\/doi.org\/10.1200\/jco.2010.29.8018.","DOI":"10.1200\/jco.2010.29.8018"},{"key":"745_CR26","doi-asserted-by":"publisher","unstructured":"Engert A, Pl\u00fctschow A, Eich HT, Lohri A, D\u00f6rken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma. 2010;363(7):640\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1000067.","DOI":"10.1056\/NEJMoa1000067"},{"key":"745_CR27","doi-asserted-by":"publisher","unstructured":"Stamatoullas A, Brice P, Bouabdallah R, Mareschal S, Camus V, Rahal I, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. 2015;170(2):179\u201384. https:\/\/doi.org\/10.1111\/bjh.13419.","DOI":"10.1111\/bjh.13419"},{"key":"745_CR28","doi-asserted-by":"publisher","unstructured":"B\u00f6ll B, Goergen H, Behringer K, Br\u00f6ckelmann PJ, Hitz F, Kerkhoff A et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. 2016;127(18):2189\u20132192. doi:https:\/\/doi.org\/10.1182\/blood-2015-11-681064. Combined 5-year PFS and OS were significantly inferior for older HL patients compared with patients aged <\u200960 years. Toxicity was also a concern with 68% of the patients developing a grade 3 to 4 toxicity and 5% of patients dying from acute toxicity, including bleomycin lung toxicity (BLT). BLT was rare in early-stage patients who received 2 cycles of ABVD, but occurred in 10% of patients who received 4 ABVD cycles, including several lethal events.","DOI":"10.1182\/blood-2015-11-681064"},{"issue":"5","key":"745_CR29","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.pupt.2005.01.007","volume":"18","author":"E Azambuja","year":"2005","unstructured":"Azambuja E, Fleck JF, Batista RG, Menna Barreto SS. Bleomycin lung toxicity: who are the patients with increased risk? Pulm Pharmacol Ther. 2005;18(5):363\u20136. https:\/\/doi.org\/10.1016\/j.pupt.2005.01.007.","journal-title":"Pulm Pharmacol Ther"},{"key":"745_CR30","doi-asserted-by":"publisher","unstructured":"Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin\u2019s lymphoma. 2005;23(30):7614\u201320. https:\/\/doi.org\/10.1200\/jco.2005.02.7243.","DOI":"10.1200\/jco.2005.02.7243"},{"key":"745_CR31","doi-asserted-by":"publisher","unstructured":"Andr\u00e9 MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, et al. Early positron emission tomography response\u2013adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. 2017;35(16):1786\u201394. https:\/\/doi.org\/10.1200\/jco.2016.68.6394.","DOI":"10.1200\/jco.2016.68.6394"},{"key":"745_CR32","doi-asserted-by":"publisher","unstructured":"Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. 2015;372(17):1598\u2013607. https:\/\/doi.org\/10.1056\/NEJMoa1408648.","DOI":"10.1056\/NEJMoa1408648"},{"key":"745_CR33","doi-asserted-by":"publisher","unstructured":"Zallio F, Tamiazzo S, Monagheddu C, Merli F, Ilariucci F, Stelitano C, et al. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). 2016;172(6):879\u201388. https:\/\/doi.org\/10.1111\/bjh.13904.","DOI":"10.1111\/bjh.13904"},{"issue":"3","key":"745_CR34","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1080\/10428190601126610","volume":"48","author":"A Kolstad","year":"2007","unstructured":"Kolstad A, Nome O, Delabie J, Lauritzsen GF, Fossa A, Holte H. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin\u2019s lymphoma. Leuk Lymphoma. 2007;48(3):570\u20136. https:\/\/doi.org\/10.1080\/10428190601126610.","journal-title":"Leuk Lymphoma"},{"key":"745_CR35","doi-asserted-by":"publisher","unstructured":"B\u00f6ll B, Pl\u00fctschow A, B\u00fcrkle C, Atta J, Pfreundschuh M, Feuring-Buske M, et al. Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial. 2019;185(1):42\u201352. https:\/\/doi.org\/10.1111\/bjh.15741.","DOI":"10.1111\/bjh.15741"},{"key":"745_CR36","doi-asserted-by":"publisher","unstructured":"Friedberg JW, Forero-Torres A, Bordoni RE, Cline VJM, Patel Donnelly D, Flynn PJ et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u2265 60 years with HL. 2017;130(26):2829\u20132837. doi:https:\/\/doi.org\/10.1182\/blood-2017-06-787200. This study combined BV with dacarbazine in older HL patients. Results showed that BV + dacarbazine had improved outcomes over BV monotherapy. Peripheral neuropathy was fairly prominent, including grade 3 (i.e., affecting self-care ADLs).","DOI":"10.1182\/blood-2017-06-787200"},{"key":"745_CR37","doi-asserted-by":"publisher","unstructured":"Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP Alternating with ABVD. 1992;327(21):1478\u201384. https:\/\/doi.org\/10.1056\/nejm199211193272102.","DOI":"10.1056\/nejm199211193272102"},{"key":"745_CR38","doi-asserted-by":"publisher","unstructured":"Radford JA, Crowther D, Rohatiner AZ, Ryder WD, Gupta RK, Oza A, et al. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP\/EVA, in the initial treatment of Hodgkin\u2019s disease. 1995;13(9):2379\u201385. https:\/\/doi.org\/10.1200\/jco.1995.13.9.2379.","DOI":"10.1200\/jco.1995.13.9.2379"},{"issue":"Supplement_1","key":"745_CR39","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1182\/blood-2019-123572\/J","volume":"134","author":"VM Orellana-Noia","year":"2019","unstructured":"Orellana-Noia VM, Isaac K, Wages NA, Malecek M-K, Bartlett NL, Voorhees TJ, et al. Fitness and anthracycline use in front-line therapy for older patients with classical Hodgkin lymphoma: a US multi-center retrospective analysis. Blood. 2019;134(Supplement_1):4027. https:\/\/doi.org\/10.1182\/blood-2019-123572\/J Blood.","journal-title":"Blood"},{"key":"745_CR40","doi-asserted-by":"publisher","unstructured":"Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood 2010;116(24):5103\u20135110. doi:https:\/\/doi.org\/10.1182\/blood-2010-07-259333","DOI":"10.1182\/blood-2010-07-259333"},{"key":"745_CR41","doi-asserted-by":"publisher","unstructured":"Mir R, Anderson J, Strauchen J, Nissen NI, Cooper MR, Rafla S, et al. Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. 1993;71(5):1857\u201366. https:\/\/doi.org\/10.1002\/1097-0142(19930301)71:5<1857::Aid-cncr2820710524>3.0.Co;2-b.","DOI":"10.1002\/1097-0142(19930301)71:5<1857::Aid-cncr2820710524>3.0.Co;2-b"},{"issue":"1","key":"745_CR42","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/annonc\/mdi023\/J","volume":"16","author":"V Ballova","year":"2005","unstructured":"Ballova V, R\u00fcffer J-U, Haverkamp H, Pfistner B, M\u00fcller-Hermelink HK, D\u00fchmke E, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin\u2019s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Annals of Oncology. 2005;16(1):124\u201331. https:\/\/doi.org\/10.1093\/annonc\/mdi023\/J Annals of Oncology.","journal-title":"Annals of Oncology"},{"key":"745_CR43","doi-asserted-by":"publisher","unstructured":"Halbsguth TV, Nogov\u00e1 L, Mueller H, Sieniawski M, Eichenauer DA, Schober T, et al. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). 2010;116(12):2026\u201332. https:\/\/doi.org\/10.1182\/blood-2009-11-253211\/J Blood.","DOI":"10.1182\/blood-2009-11-253211\/J"},{"issue":"Supplement_1","key":"745_CR44","doi-asserted-by":"publisher","first-page":"5285","DOI":"10.1182\/blood-2019-126704\/J","volume":"134","author":"M Wilson","year":"2019","unstructured":"Wilson M, Ogilvie C, Travers J, Martin M, Allan J, McKay P, et al. ACOPP Chemotherapy for Frontline Treatment of Older Patients with Hodgkin Lymphoma - a Pilot Study. Blood. 2019;134(Supplement_1):5285. https:\/\/doi.org\/10.1182\/blood-2019-126704\/J Blood.","journal-title":"Blood"},{"key":"745_CR45","doi-asserted-by":"publisher","unstructured":"B\u00f6ll B, Bredenfeld H, G\u00f6rgen H, Halbsguth T, Eich HT, Soekler M, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. 2011;118(24):6292\u20138. https:\/\/doi.org\/10.1182\/blood-2011-07-368167\/J Blood.","DOI":"10.1182\/blood-2011-07-368167\/J"},{"issue":"Supplement_1","key":"745_CR46","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1182\/blood-2019-129016","volume":"134","author":"H Ghesquieres","year":"2019","unstructured":"Ghesquieres H, Casasnovas O, Nicolas-Virelizier E, Gandhi Laurent D, Delwail V, Touati M, et al. Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in first line therapy for older patients with advanced-stage classical Hodgkin lymphoma: results of a prospective multicenter phase II trial of the Lymphoma Study Association (LYSA). Blood. 2019;134(Supplement_1):2832. https:\/\/doi.org\/10.1182\/blood-2019-129016 Blood.","journal-title":"Blood"},{"key":"745_CR47","doi-asserted-by":"publisher","unstructured":"Levis A, Pietrasanta D, Anselmo AP, Ambrosetti A, Bertini M. Treatment of elderly Hodgkin\u2019s lymphoma Patients. The experience of the Italian Lymphoma Intergroup. 2002;88(1_suppl1):S29\u201331. https:\/\/doi.org\/10.1177\/030089160208800109.","DOI":"10.1177\/030089160208800109"},{"issue":"2","key":"745_CR48","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/bjc.1977.187","volume":"36","author":"TJ McElwain","year":"1977","unstructured":"McElwain TJ, Toy J, Smith E, Peckham MJ, Austin DE. A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin\u2019s disease. Br J Cancer. 1977;36(2):276\u201380. https:\/\/doi.org\/10.1038\/bjc.1977.187.","journal-title":"Br J Cancer"},{"issue":"4","key":"745_CR49","doi-asserted-by":"publisher","first-page":"447","DOI":"10.7326\/0003-4819-101-4-447\/J","volume":"101","author":"RF BAKEMEIER","year":"1984","unstructured":"BAKEMEIER RF, ANDERSON JR, COSTELLO W, ROSNER G, HORTON J, GLICK JH, et al. BCVPP chemotherapy for advanced Hodgkin\u2019s disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP Regimen: results of the Eastern Cooperative Oncology Group Study. Ann Intern Med. 1984;101(4):447\u201356. https:\/\/doi.org\/10.7326\/0003-4819-101-4-447\/J Annals of Internal Medicine.","journal-title":"Ann Intern Med"},{"key":"745_CR50","doi-asserted-by":"publisher","unstructured":"Friedberg JW, Forero-Torres A, Holkova B, Goldschmidt JH, Boccia RV, Bordoni R, et al. Long-term follow-up of brentuximab vedotin \u00b1 dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma. 2018;36(15_suppl):7542. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.7542. As a follow-up to Friedberg\u2019s 2017 study of BV + dacarbazine, updated outcomes reported with 3-year PFS of 52% and a 3-year OS of 90%.","DOI":"10.1200\/JCO.2018.36.15_suppl.7542"},{"key":"745_CR51","doi-asserted-by":"publisher","unstructured":"Boell B, Foss\u00e5 A, Goergen H, Kamper P, Leppa S, Molin D, et al. B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in older patients with advanced-stage Hodgkin lymphoma: results of a phase II intergroup trial by the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG). 2018;132(Suppl 1):926. https:\/\/doi.org\/10.1182\/blood-2018-99-119363\/J Blood.","DOI":"10.1182\/blood-2018-99-119363\/J"},{"key":"745_CR52","doi-asserted-by":"publisher","unstructured":"B\u00f6ll B, Goergen H, Arndt N, Meissner J, Krause SW, Schnell R, et al. Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group. 2013;31(35):4431\u20137. https:\/\/doi.org\/10.1200\/jco.2013.49.8246.","DOI":"10.1200\/jco.2013.49.8246"},{"key":"745_CR53","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/bmt.2010.294","volume":"46","author":"N Puig","year":"2011","unstructured":"Puig N, Pintilie M, Seshadri T, Al-Farsi K, Franke N, Keating A, et al. High-dose chemotherapy and auto-SCT in elderly patients with Hodgkins lymphoma. Bone Marrow Transplant. 2011;46:1339\u201344. https:\/\/doi.org\/10.1038\/bmt.2010.294.","journal-title":"Bone Marrow Transplant"},{"key":"745_CR54","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/bmt.2016.76","volume":"51","author":"A Stamatoullas","year":"2016","unstructured":"Stamatoullas A, Brice P, Gueye MS, Mareschal S, Chevallier P, Bouabdallah R, et al. Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin\u2019s lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC). Bone Marrow Transplant. 2016;51:928\u201332. https:\/\/doi.org\/10.1038\/bmt.2016.76.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"745_CR55","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.bbmt.2017.03.030","volume":"23","author":"SR Pingali","year":"2017","unstructured":"Pingali SR, Saliba RM, Anderlini P, Hosing C, Khouri I, Alousi AM, et al. Age over fifty-five years at diagnosis increases risk of second malignancies after autologous transplantation for patients with Hodgkin lymphoma. Biol Blood Marrow Transplant. 2017;23(7):1059\u201363. https:\/\/doi.org\/10.1016\/j.bbmt.2017.03.030.","journal-title":"Biol Blood Marrow Transplant"},{"key":"745_CR56","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez C, Jorge AS, Pereira A, Moreno M, N\u00fa\u00f1ez J, Gayoso J, et al. Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed\/refractory Hodgkin\u2019s lymphoma in patients older than 50 years. 2017;96(1):9\u201316. https:\/\/doi.org\/10.1007\/s00277-016-2832-6.","DOI":"10.1007\/s00277-016-2832-6"},{"key":"745_CR57","doi-asserted-by":"publisher","unstructured":"Tonialini L, Stefoni V, Re A, Lleshi A, Bonfichi M, Pinto A et al. A phase II study of brentuximab vedotin (BV) in the treatment of elderly Hodgkin lymphoma (HL) patients at first relapse or with primary refractory disease\u2014FIL_BVHD01. Blood 2018;132(Suppl 1):2920. doi:https:\/\/doi.org\/10.1182\/blood-2018-99-111812","DOI":"10.1182\/blood-2018-99-111812"},{"key":"745_CR58","doi-asserted-by":"publisher","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. 2015;372(4):311\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1411087.","DOI":"10.1056\/NEJMoa1411087"},{"key":"745_CR59","doi-asserted-by":"publisher","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. 2018;36(14):1428\u201339. https:\/\/doi.org\/10.1200\/jco.2017.76.0793.","DOI":"10.1200\/jco.2017.76.0793"},{"key":"745_CR60","doi-asserted-by":"publisher","unstructured":"Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 2018;131(11):1183\u201394. https:\/\/doi.org\/10.1182\/blood-2017-10-811224\/","DOI":"10.1182\/blood-2017-10-811224\/"},{"issue":"9","key":"745_CR61","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283\u201394. https:\/\/doi.org\/10.1016\/S1470-2045(16)30167-X.","journal-title":"Lancet Oncol"},{"issue":"19","key":"745_CR62","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125\u201332. https:\/\/doi.org\/10.1200\/JCO.2016.72.1316.","journal-title":"J Clin Oncol"},{"issue":"Supplement_1","key":"745_CR63","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/blood-2019-124866\/J","volume":"134","author":"CA Yasenchak","year":"2019","unstructured":"Yasenchak CA, Bordoni R, Yazbeck V, Patel-Donnelly D, Anderson T, Larson T, et al. Phase 2 study of frontline brentuximab vedotin plus nivolumab in patients with Hodgkin lymphoma Aged \u226560 years. Blood. 2019;134(Supplement_1):237. https:\/\/doi.org\/10.1182\/blood-2019-124866\/J Blood.","journal-title":"Blood."},{"key":"745_CR64","doi-asserted-by":"publisher","unstructured":"Ramchandren R, Domingo-Dom\u00e8nech E, Rueda A, Trn\u011bn\u00fd M, Feldman TA, Lee HJ, et al. Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study. 2019;37(23):1997\u20132007. https:\/\/doi.org\/10.1200\/jco.19.00315.","DOI":"10.1200\/jco.19.00315"},{"issue":"Supplement_1","key":"745_CR65","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1182\/blood-2019-129553","volume":"134","author":"ME Zettler","year":"2019","unstructured":"Zettler ME, Nabhan C, Gajra A, Feinberg B. Adverse events in elderly Hodgkin lymphoma patients treated with pembrolizumab or nivolumab in the real world. Blood. 2019;134(Supplement_1):3490. https:\/\/doi.org\/10.1182\/blood-2019-129553 Blood.","journal-title":"Blood"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00745-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-020-00745-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00745-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T23:50:52Z","timestamp":1619135452000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-020-00745-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["745"],"URL":"https:\/\/doi.org\/10.1007\/s11864-020-00745-9","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]},"assertion":[{"value":"23 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Jordan Carter declares that he has no conflict of interest. Kevin David declares that he has no conflict of interest. Athena Kritharis declares that she has no conflict of interest. Andrew Evens has served on advisory boards for Seattle Genetics, Bayer, Verastem Oncology, Pharmacyclics, Takeda, and Merck.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"42"}}